Patents by Inventor Catherine Anne Foss

Catherine Anne Foss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents
    Patent number: 10039845
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 7, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Catherine Anne Foss
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS
    Publication number: 20180085478
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Application
    Filed: June 30, 2017
    Publication date: March 29, 2018
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, CATHERINE ANNE FOSS
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents
    Patent number: 9694091
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 4, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Catherine Anne Foss
  • Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation
    Patent number: 9498546
    Abstract: The present invention provides analog compounds of DPA-713 which specifically bind the translocator protein (TSPO), which is upregulated in activated leukocytes, some malignant tumors and tissues involved in steroid biogenesis. These compounds are linked via a linking moiety to a variety of imaging agents, including, for example, near infra-red dyes. The compounds of the present invention are useful for both pre-clinical near-IR fluorescence imaging (NIRF) and use in optically-guided interventions including NIRF endoscopy. Methods of use in diagnosis and treatment of TSPO related disease are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 22, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin Gilbert Pomper, Haofan Wang, Catherine Anne Foss
  • LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS
    Publication number: 20150246144
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, CATHERINE ANNE FOSS
  • SYNTHESIS AND APPLICATION OF NOVEL IMAGING AGENTS CONJUGATED TO DPA 713 ANALOGS FOR IMAGING INFLAMMATION
    Publication number: 20150044141
    Abstract: The present invention provides analog compounds of DPA-713 which specifically bind the translocator protein (TSPO), which is upregulated in activated leukocytes, some malignant tumors and tissues involved in steroid biogenesis. These compounds are linked via a linking moiety to a variety of imaging agents, including, for example, near infra-red dyes. The compounds of the present invention are useful for both pre-clinical near-IR fluorescence imaging (NIRF) and use in optically-guided interventions including NIRF endoscopy. Methods of use in diagnosis and treatment of TSPO related disease are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin Gilbert Pomper, Haofan Wang, Catherine Anne Foss